Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Nodal Staging in Lung Cancer A Risk Stratification Model for Lymph Nodes Classified as Negative by EBUS-TBNA

Nodal Staging in Lung Cancer A Risk Stratification Model for Lymph Nodes Classified as Negative... ORIgINAL ARTICLE Nodal Staging in Lung Cancer A Risk Stratification Model for Lymph Nodes Classified as Negative by EBUS-TBNA Matthew Evison,*† Julie Morris,‡ Julie Martin,* Rajesh Shah,§ Philip V. Barber,* Richard Booton,*† and Philip A. J. Crosbie*† 35 of 54 and 24 of 37 lymph nodes classified as high risk were proven Background: Over the last 10 years, endobronchial ultrasound- malignant. The negative predictive value of the risk stratification guided transbronchial needle aspiration (EBUS-TBNA) has become model for the derivation set and validation set was 99.3% (95% con- established as the first-line nodal staging procedure of choice for fidence interval 96.1%–99.6%) and 97.9% (95% confidence interval lung cancer patients. However, the pathway for patients following a 92%–99.6%), respectively. negative EBUS-TBNA has not been clearly defined. The primary aim Conclusion: This risk stratification model may assist lung cancer of this study was to develop and validate a risk stratification model multidisciplinary teams in deciding which patients need further stag- to categorize lymph nodes deemed negative by EBUS-TBNA into ing procedures and which may proceed directly to treatment after a “low-risk” and “high-risk” groups, where “risk” refers to the risk of negative EBUS. false negative sampling. Methods: A retrospective analysis of a prospectively maintained Key http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Nodal Staging in Lung Cancer A Risk Stratification Model for Lymph Nodes Classified as Negative by EBUS-TBNA

Journal of Thoracic Oncology , Volume 10 (1) – Jan 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/nodal-staging-in-lung-cancer-a-risk-stratification-model-for-lymph-IXdkMFvW3x

References (27)

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000348
pmid
25371076
Publisher site
See Article on Publisher Site

Abstract

ORIgINAL ARTICLE Nodal Staging in Lung Cancer A Risk Stratification Model for Lymph Nodes Classified as Negative by EBUS-TBNA Matthew Evison,*† Julie Morris,‡ Julie Martin,* Rajesh Shah,§ Philip V. Barber,* Richard Booton,*† and Philip A. J. Crosbie*† 35 of 54 and 24 of 37 lymph nodes classified as high risk were proven Background: Over the last 10 years, endobronchial ultrasound- malignant. The negative predictive value of the risk stratification guided transbronchial needle aspiration (EBUS-TBNA) has become model for the derivation set and validation set was 99.3% (95% con- established as the first-line nodal staging procedure of choice for fidence interval 96.1%–99.6%) and 97.9% (95% confidence interval lung cancer patients. However, the pathway for patients following a 92%–99.6%), respectively. negative EBUS-TBNA has not been clearly defined. The primary aim Conclusion: This risk stratification model may assist lung cancer of this study was to develop and validate a risk stratification model multidisciplinary teams in deciding which patients need further stag- to categorize lymph nodes deemed negative by EBUS-TBNA into ing procedures and which may proceed directly to treatment after a “low-risk” and “high-risk” groups, where “risk” refers to the risk of negative EBUS. false negative sampling. Methods: A retrospective analysis of a prospectively maintained Key

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jan 1, 2015

There are no references for this article.